Guanfacine Tablet, Extended Release
Product Images NDC 63629-8203

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 63629-8203). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Image 05)

A line graph comparing plasma concentration of Guanfacine over 24 hours between guanfacine extended-release tablets 1 mg QD and Tenex 1 mg QD. The y-axis shows guanfacine plasma concentration in ng/mL, and the x-axis shows time in hours. Guanfacine extended-release shows a gradual rise and sustained levels, while Tenex peaks higher earlier and declines more rapidly.*

FDA Label Image

Figure 2 (Image 06)

A pharmacokinetic (PK) chart showing fold changes and 90% confidence intervals for Cmax and AUC values of guanfacine when coadministered with various substances. The chart compares CYP3A4/5 inhibitors, CYP3A4 inducers, and other drugs such as ketoconazole, fluconazole, rifampin, efavirenz, oral methylphenidate, and lisdexamfetamine dimesylate, with fold change values relative to a reference.*

FDA Label Image

Figure 3 (Image 07)

A pharmacokinetic chart showing fold changes and 90% confidence intervals for Cmax and AUC of oral methylphenidate and lisdexamfetamine dimesylate compared to a reference, with a scale from 0.0 to 2.0 on the x-axis labeled "Change relative to reference."*

FDA Label Image

Label (Lbl636298203)

Label for Guanfacine ER 2 mg tablets, supplied by Bryant Ranch Prepack. The label states each tablet contains guanfacine hydrochloride 2 mg and the package contains 30 tablets. Storage instructions note a temperature range of 20° to 25° C with permitted excursions. The label includes the NDC 63629-8203-01 and shows the BRP Pharmaceuticals logo.*

FDA Label Image

Spl-guanfacine-figure 4 (Spl Guanfacine Figure 4)

A line graph depicting treatment failure percentage over time (days) comparing Placebo and SPD503 groups. The solid line represents Placebo, showing higher treatment failure rates that increase steadily up to about 65%. The dashed line represents SPD503, with lower failure rates plateauing near 50% over approximately 200 days.*

FDA Label Image

Structure (Structure)

Chemical structure of Guanfacine hydrochloride showing its molecular arrangement with chlorine atoms attached to the aromatic ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.